// App-Quantinova.ai

101 : A Phase lb Dose Escalation Study of the OX40 Agonist MOXR0916 and the PD-L1 Inhibitor Atezolizumab in Patients with Advanced Solid Tumors

Researchers

Presenter

  • Jeffrey R. Infante

Principal Investigators

  • Michael J. Pishvaian

  • Laura Quan Man Chow

  • Grant A. McArthur

  • Todd Michael Bauer

  • Stephen V. Liu

  • Shahneen Kaur Sandhu

  • Frank Yung-Chin Tsai

  • Jeong Kim

  • Eric Stefanich

  • Chi-Chung Li

  • Houston Gilbert

  • BRUCE MCCALL

  • Maria S. Anderson

  • Mahrukh Huseni

  • Ina Park Rhee

  • Lillian L. Siu

  • Michael S. Gordon

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Seattle Cancer Care Alliance, Seattle, WA

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Georgetown University, Washington, DC

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Genentech, Inc., South San Francisico, CA

  • Pinnacle Oncology Hematology/HonorHealth Research Institute, Scottsdale, AZ

Locations

  • United States

  • Canada

  • Australia

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Vonlerolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02410512

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved